{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:51:36Z","timestamp":1793656296018,"version":"4.5.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40257-021-00660-1","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T10:03:20Z","timestamp":1639389800000},"page":"207-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efinaconazole in Onychomycosis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"660_CR1","first-page":"1","volume":"30","author":"TC Vlahovic","year":"2021","unstructured":"Vlahovic TC, Gupta AK. Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients. Expert Rev Anti Infect Ther. 2021;30:1\u201313.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"11","key":"660_CR2","first-page":"762","volume":"88","author":"DP Westerberg","year":"2013","unstructured":"Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762\u201370.","journal-title":"Am Fam Physician"},{"key":"660_CR3","unstructured":"Penlac\u00ae Nail Lacquer (ciclopirox) Topical Solution, 8%. 2004. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21022s004lbl.pdf. Accessed 06 Aug 2021."},{"key":"660_CR4","unstructured":"Penlac\u00ae (ciclopirox topical 8% w\/w solution) product monograph. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21022s004lbl.pdf. Accessed 16 Sep 2021."},{"issue":"4","key":"660_CR5","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1067\/mjd.2000.109072","volume":"43","author":"M Bohn","year":"2000","unstructured":"Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000;43(4):S57\u201369.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"660_CR6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jaad.2020.06.1004","volume":"84","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Elewski B, Sugarman JL, Rosen T, Vlahovic TC, Gupta AK, et al. Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: open-label phase 4 study. J Am Acad Dermatol. 2021;84(4):1140\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"660_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2015.04.010","volume":"73","author":"BE Elewski","year":"2015","unstructured":"Elewski BE, Aly R, Baldwin SL, Soto RFG, Rich P, Weisfeld M, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73(1):62\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"660_CR8","first-page":"1394","volume":"13","author":"BE Elewski","year":"2014","unstructured":"Elewski BE, Pollak RA, Pillai R, Olin JT. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space. J Drugs Dermatol. 2014;13(11):1394\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"660_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","volume":"68","author":"BE Elewski","year":"2013","unstructured":"Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"660_CR10","first-page":"815","volume":"13","author":"AK Gupta","year":"2014","unstructured":"Gupta AK, Elewski BE, Sugarman JL, Ieda C, Kawabata H, Kang R, et al. The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials. J Drugs Dermatol. 2014;13(7):815\u201320.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"660_CR11","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","volume":"43","author":"AK Gupta","year":"2000","unstructured":"Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4):S70\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"660_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2165\/00003495-199549010-00008","volume":"49","author":"M Haria","year":"1995","unstructured":"Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995;49(1):103\u201320.","journal-title":"Drugs"},{"key":"660_CR13","doi-asserted-by":"crossref","unstructured":"Hold K, Bullington R, Jones T, Beutner K. In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis: P1816. J Am Acad Dermatol. 2007;56(2).","DOI":"10.1016\/j.jaad.2006.10.596"},{"key":"660_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2230.1992.tb00277.x","volume":"17","author":"J Lauharanta","year":"1992","unstructured":"Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol. 1992;17:41\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"660_CR15","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/j.1468-3083.2012.04529.x","volume":"27","author":"D Monti","year":"2013","unstructured":"Monti D, Herranz U, Dal Bo L, Subissi A. Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects. J Eur Acad Dermatol Venereol. 2013;27(2):e153\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"660_CR16","first-page":"1388","volume":"13","author":"M Sakamoto","year":"2014","unstructured":"Sakamoto M, Sugimoto N, Kawabata H, Yamakawa E, Kodera N, Pillai R, et al. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. J Drugs Dermatol. 2014;13(11):1388\u201392.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"660_CR17","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1128\/AAC.00111-14","volume":"58","author":"K Sugiura","year":"2014","unstructured":"Sugiura K, Sugimoto N, Hosaka S, Katafuchi-Nagashima M, Arakawa Y, Tatsumi Y, et al. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrob Agents Chemother. 2014;58(7):3837\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"660_CR18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/myc.12528","volume":"59","author":"J Gasser","year":"2016","unstructured":"Gasser J, Pagani E, Vittadello F, Nobile C, Zampieri P, Eisendle K. Frequency, type and treatment of fungal pathogens in toenail onychomycosis in the central Alpine region of South Tyrol, northern Italy\u2014a 10-year retrospective study from 2004 to 2013. Mycoses. 2016;59(12):760\u20134.","journal-title":"Mycoses"},{"key":"660_CR19","unstructured":"Product monograph of JUBLIA\u00ae (efinaconazole), topical solution, 10% w\/w (Bausch Health, Canada Inc.). 2020. https:\/\/pdf.hres.ca\/dpd_pm\/00054721.PDF. Accessed 01 Sep 2021."},{"key":"660_CR20","unstructured":"Highlights of prescribing information, JUBLIA\u00ae (efinaconazole) topical solution (FDA label). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203567s009lbl.pdf. Accessed 01 Sep 2021."},{"issue":"4","key":"660_CR21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1128\/AAC.02056-12","volume":"57","author":"WJ Jo Siu","year":"2013","unstructured":"Jo Siu WJ, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob Agents Chemother. 2013;57(4):1610\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"660_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jof3020020","volume":"3","author":"A Tupaki-Sreepurna","year":"2017","unstructured":"Tupaki-Sreepurna A, Jishnu BT, Thanneru V, Sharma S, Gopi A, Sundaram M, et al. An assessment of in vitro antifungal activities of efinaconazole and itraconazole against common non-dermatophyte fungi causing onychomycosis. J Fungi (Basel). 2017;3(2):20.","journal-title":"J Fungi (Basel)."},{"key":"660_CR23","unstructured":"Nachrichtendienst V. Almirall and Kaken Pharmaceutical enter into a license and distribution agreement for European rights to the topical formulation of efinaconazole. 2021. https:\/\/www.prnewswire.com\/de\/pressemitteilungen\/almirall-and-kaken-pharmaceutical-enter-into-a-license-and-distribution-agreement-for-european-rights-to-the-topical-formulation-of-efinaconazole-850637563.html. Accessed 22 Sep 2021."},{"issue":"12","key":"660_CR24","first-page":"1457","volume":"13","author":"LH Kircik","year":"2014","unstructured":"Kircik LH. Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach. J Drugs Dermatol. 2014;13(12):1457\u201361.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"660_CR25","first-page":"859","volume":"14","author":"AK Gupta","year":"2015","unstructured":"Gupta AK, Pillai R. The presence of an air gap between the nail plate and nail bed in onychomycosis patients: treatment implications for topical therapy. J Drugs Dermatol. 2015;14(8):859\u201363.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"660_CR26","first-page":"20","volume":"6","author":"JQ Del Rosso","year":"2013","unstructured":"Del Rosso JQ, Reece B, Smith K, Miller T. Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential. J Clin Aesthet Dermatol. 2013;6(3):20.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"8","key":"660_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/1346-8138.14935","volume":"46","author":"K Iozumi","year":"2019","unstructured":"Iozumi K, Abe M, Ito Y, Uesugi T, Onoduka T, Kato I, et al. Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: a multicenter, single-arm study. J Dermatol. 2019;46(8):641\u201351.","journal-title":"J Dermatol"},{"issue":"1","key":"660_CR28","first-page":"5","volume":"26","author":"AK Gupta","year":"2021","unstructured":"Gupta AK, Cooper EA. Long-term efficacy and safety of once-daily Efinaconazole 10% topical solution (Jublia) for dermatophyte toenail onychomycosis: an interim analysis. Skin Ther Lett. 2021;26(1):5\u201310.","journal-title":"Skin Ther Lett."},{"key":"660_CR29","unstructured":"Rich P. Efinaconazole topical solution, 10%: the benefits of treating onychomycosis early. J Drugs Dermatol. 2015."},{"issue":"3","key":"660_CR30","first-page":"197","volume":"96","author":"T Rosen","year":"2015","unstructured":"Rosen T. Evaluation of gender as a clinically relevant outcome variable in the treatment of onychomycosis with efinaconazole topical solution 10%. Cutis. 2015;96(3):197\u2013201.","journal-title":"Cutis"},{"key":"660_CR31","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/ijd.15739","volume":"60","author":"AK Gupta","year":"2021","unstructured":"Gupta AK, Venkataraman M, Anbalagan N, Guenin EP. One size does not fit all: the need for individualized treatment based on factors that may affect the therapeutic outcome of efinaconazole 10% solution for the treatment of toenail onychomycosis. Int J Dermatol. 2021;60:1296\u2013302.","journal-title":"Int J Dermatol"},{"issue":"10","key":"660_CR32","first-page":"1186","volume":"13","author":"TC Vlahovic","year":"2014","unstructured":"Vlahovic TC, Joseph WS. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. J Drugs Dermatol. 2014;13(10):1186\u201390.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"660_CR33","first-page":"38","volume":"8","author":"BE Elewski","year":"2015","unstructured":"Elewski BE, Tosti A. Risk factors and comorbidities for onychomycosis: implications for treatment with topical therapy. J Clin Aesthet Dermatol. 2015;8(11):38.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"6","key":"660_CR34","first-page":"24","volume":"8","author":"DA Rodriguez","year":"2015","unstructured":"Rodriguez DA. Efinaconazole topical solution, 10%, for the treatment of mild and moderate toenail onychomycosis. J Clin Aesthet Dermatol. 2015;8(6):24.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"10","key":"660_CR35","first-page":"1260","volume":"15","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Korotzer A. Topical treatment of onychomycosis and clinically meaningful outcomes. J Drugs Dermatol. 2016;15(10):1260\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"660_CR36","first-page":"42","volume":"9","author":"JQ Del Rosso","year":"2016","unstructured":"Del Rosso JQ. Onychomycosis of toenails and post-hoc analyses with Efinaconazole 10% solution once-daily treatment: impact of disease severity and other concomitant associated factors on selection of therapy and therapeutic outcomes. J Clin Aesthet Dermatol. 2016;9(2):42\u20137.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"11","key":"660_CR37","first-page":"25","volume":"7","author":"A Tosti","year":"2014","unstructured":"Tosti A, Elewski BE. Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life. J Clin Aesthet Dermatol. 2014;7(11):25.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"4","key":"660_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000514361","volume":"7","author":"AK Gupta","year":"2021","unstructured":"Gupta AK, Venkataraman M, Quinlan EM, Gupta MA, Anbalagan N, Lyons R. More than nail deep: the effect of efinaconazole 10% treatment on the quality of life in patients with onychomycosis: a post hoc study. Skin Appendage Disord. 2021;7(4):272\u20139.","journal-title":"Skin Appendage Disord."},{"key":"660_CR39","doi-asserted-by":"crossref","unstructured":"Foley K, Gupta AK, Versteeg S, Mays R, Villanueva E, John D. Topical and device\u2010based treatments for fungal infections of the toenails. Cochrane Database Syst Rev. 2020;(1).","DOI":"10.1002\/14651858.CD012093.pub2"},{"issue":"1","key":"660_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/pde.12986","volume":"34","author":"CR Totri","year":"2017","unstructured":"Totri CR, Feldstein S, Admani S, Friedlander SF, Eichenfield LF. Epidemiologic analysis of onychomycosis in the San Diego pediatric population. Pediatr Dermatol. 2017;34(1):46\u20139.","journal-title":"Pediatr Dermatol"},{"key":"660_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1810607","volume":"26","author":"AK Gupta","year":"2020","unstructured":"Gupta AK, Venkataraman M, Shear NH, Piguet V. Onychomycosis in children\u2014review on treatment and management strategies. J Dermatolog Treat. 2020;26:1\u201312.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"660_CR42","first-page":"1076","volume":"20","author":"SR Lipner","year":"2021","unstructured":"Lipner SR, Joseph WS, Vlahovic TC, Scher RK, Rich P, Ghannoum M, et al. Therapeutic recommendations for the treatment of toenail onychomycosis in the US. J Drugs Dermatol. 2021;20(10):1076\u201384.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"660_CR43","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/1346-8138.16035","volume":"48","author":"S Watanabe","year":"2021","unstructured":"Watanabe S, Iozumi K, Abe M, Ito Y, Uesugi T, Onoduka T, et al. Clinical effectiveness of efinaconazole 10% solution for treatment of onychomycosis with longitudinal spikes. J Dermatol. 2021;48(10):1474\u201381.","journal-title":"J Dermatol"},{"key":"660_CR44","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. 2020. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 17 Dec 2020."},{"issue":"4","key":"660_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1517\/14656566.2016.1146687","volume":"17","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Cernea M. How effective is efinaconazole in the management of onychomycosis? Expert Opin Pharmacother. 2016;17(4):611\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"660_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.reprotox.2014.12.007","volume":"52","author":"M Glynn","year":"2015","unstructured":"Glynn M, Jo W, Minowa K, Sanada H, Nejishima H, Matsuuchi H, et al. Efinaconazole: developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015;52:18\u201325.","journal-title":"Reprod Toxicol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00660-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T10:18:39Z","timestamp":1646907519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00660-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00660-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"14 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AKG has conducted clinical trials and been a speaker for Bausch Health in Canada; he is a consultant for Ortho Diagnostics (USA). MT has no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare that human ethics approval was not required for this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conception of the manuscript was done by AKG. The work was drafted by MT and substantively revised by AKG and MT.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}